The natural history of dihydrolipoamide dehydrogenase deficiency in Israel.
DLD
E3
dihydrolipoamide dehydrogenase (DLD) deficiency
lipoamide dehydrogenase (LADH)
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
revised:
13
06
2024
received:
21
01
2024
accepted:
20
06
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Dihydrolipoamide dehydrogenase (DLD) deficiency is an ultra-rare autosomal-recessive inborn error of metabolism, affecting no less than five mitochondrial multienzyme complexes. With approximately 30 patients reported to date, DLD deficiency was associated with three major clinical presentations: an early-onset encephalopathic phenotype with metabolic acidosis, a predominantly hepatic presentation with liver failure, and a rare myopathic phenotype. To elucidate the demographic, phenotypic, and molecular characteristics of patients with DLD deficiency within the Israeli population, data were collected from metabolic disease specialists in four large tertiary medical centers in the center and south of Israel. Pediatric and adult patients with biallelic variants in DLD were included in the study. A total of 53 patients of 35 families were included in the cohort. Age at presentation ranged between birth and 10 years. Wide phenotypic variability was observed, from asymptomatic individuals in their sixth decade of life, to severe, neonatal-onset disease with devastating neurological sequelae. Six DLD variants were noted, the most common of which was the c.685G>T (p.G229C) variant in homozygous form (24/53 patients, 45.3%; 13/35 families), observed mostly among patients of Ashkenazi-Jewish descent, followed by the homozygous c.1436A>T (p.D479V) variant, found in 20 patients of Bedouin descent (37.7%; 16/35 families). Overall, patients did not necessarily present as one of the previously described distinct clinical phenotypes. DLD deficiency is a panethnic disorder, with significant phenotypic variability, and comprises a continuum, rather than three distinct clinical presentations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
Patel MS, Roche TE. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J. 1990;4(14):3224‐3233.
Wongkittichote P, Cuddapah SR, Master SR, et al. Biochemical characterization of patients with dihydrolipoamide dehydrogenase deficiency. JIMD Rep. 2023;64(5):367‐374.
Saudubray JM, Baumgartner M, Walter J. Inborn Metabolic Diseases: Diagnosis and Treatment. 6th ed. Springer; 2016.
Shaag A, Saada A, Berger I, et al. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet. 1999;82(2):177‐182.
Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat. 2010;31(11):1240‐1250.
Cameron JM, Levandovskiy V, Mackay N, et al. Novel mutations in dihydrolipoamide dehydrogenase deficiency in two cousins with borderline‐normal PDH complex activity. Am J Med Genet A. 2006;140(14):1542‐1552.
Odièvre MH, Chretien D, Munnich A, et al. A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of alpha‐ketoglutarate dehydrogenase deficiency. Hum Mutat. 2005;25(3):323‐324.
Elpeleg ON, Shaag A, Glustein JZ, Anikster Y, Joseph A, Saada A. Lipoamide dehydrogenase deficiency in Ashkenazi Jews: an insertion mutation in the mitochondrial leader sequence. Hum Mutat. 1997;10(3):256‐257.
Brassier A, Ottolenghi C, Boutron A, et al. Dihydrolipoamide dehydrogenase deficiency: a still overlooked cause of recurrent acute liver failure and Reye‐like syndrome. Mol Genet Metab. 2013;109(1):28‐32.
Hong YS, Korman SH, Lee J, et al. Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy. J Inherit Metab Dis. 2003;26(8):816‐818.
Sansaricq C, Pardo S, Balwani M, Grace M, Raymond K. Biochemical and molecular diagnosis of lipoamide dehydrogenase deficiency in a North American Ashkenazi Jewish family. J Inherit Metab Dis. 2006;29(1):203‐204.
Aptoxitzer I, Saada A, Faber J, Kleid D, Elpeleg ON. Liver disease in the Ashkenazi‐Jewish lipoamide dehydrogenase deficiency. J Pediatr Gastroenterol Nutr. 1997;24(5):599‐601.
Quintana E, Pineda M, Font A, et al. Dihydrolipoamide dehydrogenase (DLD) deficiency in a Spanish patient with myopathic presentation due to a new mutation in the interface domain. J Inherit Metab Dis. 2010;33(suppl 3):S315‐S319.
Carrozzo R, Torraco A, Fiermonte G, et al. Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon‐like effect of vitamin B2. Mitochondrion. 2014;18:49‐57.
Elpeleg ON, Saada AB, Shaag A, et al. Lipoamide dehydrogenase deficiency: a new cause for recurrent myoglobinuria. Muscle Nerve. 1997;20(2):238‐240.
Elpeleg ON, Ruitenbeek W, Jakobs C, Barash V, De Vivo DC, Amir N. Congenital lacticacidemia caused by lipoamide dehydrogenase deficiency with favorable outcome. J Pediatr. 1995;126(1):72‐74.
Alfarsi A, Alfadhel M, Alameer S, et al. The phenotypic spectrum of dihydrolipoamide dehydrogenase deficiency in Saudi Arabia. Mol Genet Metab Rep. 2021;29:100817.
Vaubel RA, Rustin P, Isaya G. Mutations in the dimer interface of dihydrolipoamide dehydrogenase promote site‐specific oxidative damages in yeast and human cells. J Biol Chem. 2011;286(46):40232‐40245.
Ambrus A, Adam‐Vizi V. Human dihydrolipoamide dehydrogenase (E3) deficiency: novel insights into the structural basis and molecular pathomechanism. Neurochem Int. 2018;117:5‐14.
Hong YS, Kerr DS, Craigen WJ, et al. Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Hum Mol Genet. 1996;5(12):1925‐1930.
Bedovan JK, Hage R, Shin HK, et al. Utility of specific amino acid ratios in screening for pyruvate dehydrogenase complex deficiencies and other mitochondrial disorders associated with congenital lactic acidosis and newborn screening prospects. JIMD Rep. 2020;56(1):70‐81.
Staretz‐Chacham O, Pode‐Shakked B, Kristal E, et al. The effects of a ketogenic diet on patients with dihydrolipoamide dehydrogenase deficiency. Nutrients. 2021;13(10):3523.
Quinonez SC, Thoene JG. Dihydrolipoamide dehydrogenase deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneReviews® [Internet]. University of Washington, Seattle; 2014:1993‐2024 [updated 2021 Sep 30].
Balasubramaniam S, Yaplito‐Lee J. Riboflavin metabolism: role in mitochondrial function. J Transl Genet Genom. 2020;4:285‐306.
Haviv R, Zeharia A, Belaiche C, Haimi Cohen Y, Saada A. Elevated plasma citrulline: look for dihydrolipoamide dehydrogenase deficiency. Eur J Pediatr. 2014;173(2):243‐245.
Quinonez SC, Seeley AH, Seeterlin M, Stanley E, Ahmad A. Newborn screening for dihydrolipoamide dehydrogenase deficiency: citrulline as a useful analyte. Mol Genet Metab Rep. 2014;1:345‐349.